Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.
Virios Therapeutics, Inc. (Nasdaq: VIRI) today announced the results of a pilot study performed at the University of Alabama, titled “Gastric Herpes Simplex Virus Type 1 Infection is Associated with Functional Gastrointestinal Disorders in the Presence and Absence of Comorbid Fibromyalgia: A Pilot Case-Control Study”, were published in the journal Infection. These results provide evidence for a potential mechanistic connection between active herpes virus infection and functional gastrointestinal Disorders (“FGID”), with or without comorbid fibromyalgia (“FM”), as well as the potential for combination antiviral therapy to treat patients with FGIDs and FM.
In this study, tissue biopsies were obtained from three groups of volunteers: Group 1 were those with a FGID, such as irritable bowel syndrome, functional dyspepsia, functional constipation as well as comorbid FM; Group 2 were those with FGID only; and Group 3 were control patients without FGID or FM. Epidemiologic studies suggest that FM affects approximately 2% of the population. Previous research published in Gastroenterology in 2021 found that FGIDs impact 40% of persons worldwide and affect quality of life and health care use. Neither histological gastritis nor H. pylori infection were found to be associated with FGIDs or FM.
“The data presented by Dr. Duffy were from a tissue biopsy study jointly conducted between the University of Alabama and Virios Therapeutics,” commented R. Michael Gendreau, M.D., Ph.D., Chief Medical Officer of Virios Therapeutics. “The study examined gastric mucosa biopsies from three cohorts: patients with FGID, patients with both FGID and FM, and control patients. Biopsy specimens were analyzed for the presence of active herpes virus infections. As is discussed in the publication, there was a marked increase in the presence of actively replicating herpes simplex virus type 1 (“HSV-1”) in gastric mucosal tissue from the FGID and the FGID and FM patient groups as compared to control patients.”
“This finding highlights the potential role of activated HSV-1 as a potential root cause of common chronic gastrointestinal disorders. Importantly, neither histological gastritis nor H. pylori infection were found to be associated with FGIDs or FM. This publication provides further visibility to the medical community of the potential utility of combination antiviral drug therapies, such as IMC-1, for patients with chronic illnesses such as FM and irritable bowel syndrome (“IBS”), which are often described as functional disorders,” concluded Dr. Gendreau.
Title: Gastric Herpes Simplex Virus Type 1 Infection is Associated with Functional Gastrointestinal Disorders in the Presence and Absence of Comorbid Fibromyalgia: A Pilot Case-Control Study
Authors: Carol Duffy, PhD, The Department of Biological Sciences, University of Alabama, Tuscaloosa, Alabama; William Pridgen, M.D., Tuscaloosa Surgical Associates; Rich Whitely, MD, Division of Pediatric Infectious Diseases, Department of Pediatrics, Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, Alabama.
Conclusions: Analysis of gastric mucosa biopsies revealed a significant positive association between actively replicating gastric HSV-1 and multiple functional gastrointestinal disorders, with and without concomitant FM. FGIDs including IBS, functional dysphagia, and functional dyspepsia may be related to active HSV-1 infection. Further investigation into the prevalence and possible causal nature of this association is warranted.
For more information, please visit www.virios.com.
Tags: #Virios #Therapeutics #VIRI #Featured #Publication #Highlighting #Association #Herpes #Simplex #Type #Viral #Infection #Common #Gastrointestinal #Disorders